Litcius/Paper detail

Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines

Elham Jamshidi, Amirhossein Asgary, Paria Shafiekhani, Yasaman Khajeamiri, Kawthar Mohamed, Hadi Esmaily, Sahand Jamal Rahi, Nahal Mansouri

2022Human Vaccines & Immunotherapeutics25 citationsDOIOpen Access PDF

Abstract

It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccine's antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.

Topics & Concepts

VaccinationMedicineImmunityImmunologyImmune systemAntibodyCoronavirus disease 2019 (COVID-19)Booster doseNeutralizing antibodyVirologyImmunizationInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responsesvaccines and immunoinformatics approaches
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines | Litcius